#patient-access

#patient-access

EMPAVELI is the first and only approved treatment for C3G and IC-MPGN across pediatric patients 12+, adults, and post-transplant recurrence. That's roughly 5,000 patients in the U.S., with EMPAVELI holding exclusive approval for about two-thirds. Add the European CHMP positive opinion in December 2025, and you have a rare disease franchise with global expansion potential and pricing power that typically commands gross margins north of 90%.

Longevity - or living healthier for longer - is a hot topic, drawing millions of readers to Business Insider and driving billions of dollars of investment worldwide. It's easy to see why the promise of a medical fountain of youth is enticing to both the average person and those peddling snake oil, looking to make a quick buck. That's why Business Insider is launching its Rising Stars of Longevity list, to celebrate and acknowledge those in the longevity space outpacing their peers with meaningful, impactful work.

London's position as Europe's leading clinical research hub generates profound impacts extending far beyond laboratory walls and hospital wards. Hundreds of London trials running simultaneously create a sophisticated ecosystem connecting pharmaceutical companies, research institutions, healthcare providers, and most importantly, thousands of patients seeking access to innovative treatments whilst contributing to medical advancement. This ecosystem delivers tangible economic value whilst simultaneously addressing patient needs that conventional healthcare often cannot meet.

For these patients, minutes and miles matter. Transfers risk delays at every step: co-ordination, transit and bed-waits on admission. In emergencies like neutropenic sepsis, treatment must be instant.

THE TOPLINE The FDA has stated it plans to remove all natural desiccated thyroid (NDT) products from the market within 12 months, impacting millions who rely on NDT for effective thyroid hormone replacement. Despite decades of safe use and minimal adverse event reports, the FDA demands costly approval processes that NDT manufacturers cannot realistically meet. This enforcement is part of a broader and long-term pattern of restricting access to natural and compounded medicines, limiting patient choice, and consolidating pharmaceutical industry control.

The company is tackling one of healthcare's most persistent problems: access. Known as the "front door" of healthcare, communication and scheduling systems often determine whether patients can actually secure timely care. Across the U.S., as many as 42% of patient calls and texts go unanswered during peak hours, largely due to staffing shortages and overburdened call centers. This leads to delays in care, missed appointments, and revenue loss for practices.

"Under a new law that went into effect July 1, doctors in Florida can administer unapproved stem-cell therapies for wound care, pain management, or orthopedic purposes."

The new law significantly broadens medical cannabis access in Texas by introducing an inclusive list of qualifying conditions, delivering critical wellness alternatives to patients.

It's shocking that there is so much miscommunication regarding parking for employees who have been hired expecting to park at their workplace.